238 related articles for article (PubMed ID: 35875870)
61. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.
Mo F; Mamonkin M
Methods Mol Biol; 2020; 2086():119-130. PubMed ID: 31707671
[TBL] [Abstract][Full Text] [Related]
62. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety.
Maharshi V; Diksha D; Gupta P
Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195
[TBL] [Abstract][Full Text] [Related]
63. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
[TBL] [Abstract][Full Text] [Related]
64. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
Sun W; Liang AB; Huang H; Huang XJ
Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
[TBL] [Abstract][Full Text] [Related]
65. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
66. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan.
Jo T; Yoshihara S; Okuyama Y; Fujii K; Henzan T; Kahata K; Yamazaki R; Takeda W; Umezawa Y; Fukushima K; Ashida T; Yamada-Fujiwara M; Hanajiri R; Yonetani N; Tada Y; Shimura Y; Nishikii H; Shiba N; Mimura N; Ando J; Sato T; Nakashima Y; Ikemoto J; Iwaki K; Fujiwara SI; Ri M; Nagamura-Inoue T; Tanosaki R; Arai Y
Br J Haematol; 2023 Jul; 202(2):256-266. PubMed ID: 37096915
[TBL] [Abstract][Full Text] [Related]
67. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
[TBL] [Abstract][Full Text] [Related]
68. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
69. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
70. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
[TBL] [Abstract][Full Text] [Related]
71. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
72. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
73. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
74. Potential of Chimeric Antigen Receptor T-Cells in Cancer Therapy.
Desai D; Gaud RS; Shende P
Adv Exp Med Biol; 2021; 1326():39-46. PubMed ID: 33330963
[TBL] [Abstract][Full Text] [Related]
75. Changes to culture pH and dissolved oxygen can enhance chimeric antigen receptor T-cell generation and differentiation.
Lamas R; Ulrey R; Ahuja S; Sargent A
Biotechnol Prog; 2022 Sep; 38(5):e3275. PubMed ID: 35567431
[TBL] [Abstract][Full Text] [Related]
76. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
77. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
78. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
[TBL] [Abstract][Full Text] [Related]
79. CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
Zhang XW; Wu YS; Xu TM; Cui MH
Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979400
[TBL] [Abstract][Full Text] [Related]
80. Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells.
Qu Y; Dunn ZS; Chen X; MacMullan M; Cinay G; Wang HY; Liu J; Hu F; Wang P
Hum Gene Ther; 2022 Mar; 33(5-6):223-236. PubMed ID: 34225478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
